Advancing early disease and cancer screening using biophysics based Cancer Differentiation Analysis technology.
Ticker Symbol: ANPC (NASDAQ Global Market)
Early cancer screening saves lives and dramatically reduces costs.
Co-Founder, Dr. Chris Yu and Dr. Herbert Yu have assembled an integrated research and development team from both China and United States. Our research and development team has a multi-disciplinary background, and most members of this team specialize in areas related or helpful to the development of our CDA technology and device, including mechatronics, physics, biomedical science or computer science.
Anpac Bio has partnered with hospitals and medical institutions to conduct several studies in the U.S and China. Read the research Anpac Bio scientists presented at the American Society of Clinical Oncology (ASCO), the San Antonio Breast Cancer Symposium, and the Nobel Prize Laureate Summit on Biomedical Sciences.